Answers are grounded in this paper and cite their sources.
Introduction: Prediabetes, encompassing impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and intermediate glycated haemoglobin (HbA1c), affects several hundred million adults worldwide and carries a 5–10% annual risk of progression to type 2 diabetes mellitus (T2DM). Metformin is the only glucose-lowering agent endorsed by major guidelines for diabetes prevention, yet its effectiveness outside the United States Diabetes Prevention Program (DPP), in pragmatic stepwise programmes, across prediabetes phenotypes and in special populations remains uncertain. This review aimed to quantify the effectiveness and safety of metformin-based strategies for preventing progression from prediabetes to T2DM using contemporary evidence. Methods: The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. PubMed, Europe PMC, Semantic Scholar and ClinicalTrials.gov were searched from January 2011 to 12 November 2026, supplemented by citation searching. Randomized controlled trials (RCTs), comparative studies, cohort studies and case series enrolling adults with prediabetes and comparing metformin (alone, added to lifestyle intervention, or within a stepwise strategy) with placebo, lifestyle intervention or standard care were eligible; systematic reviews were excluded from synthesis but retained for discussion. Risk of bias was assessed with RoB 2 and ROBINS-I. Log-transformed hazard ratios (HR), risk ratios (RR) and incidence rate ratios were pooled with DerSimonian–Laird random-effects models, with Hartung–Knapp–Sidik–Jonkman (HKSJ) adjustment, prediction intervals, subgroup, sensitivity, meta-regression and small-study analyses. Certainty of evidence was graded with GRADE. Results: Fourteen studies (25 reports) were included: 10 RCTs, three comparative cohort studies and one case series. In eight RCTs (6,424 participants), metformin-based strategies reduced incident T2DM by 27% (pooled ratio 0.73, 95% CI 0.62–0.86; I² = 58%; HKSJ 95% CI 0.56–0.96; 95% prediction interval 0.48–1.12; moderate certainty). The isolated pharmacological effect of metformin on an identical background therapy was 0.75 (0.60–0.95; five RCTs), and lifestyle intervention with stepwise metformin versus standard care yielded 0.68 (0.53–0.88; three RCTs). Excluding the metabolic syndrome trial with fasting-glucose-only ascertainment removed most heterogeneity (0.79, 0.72–0.87; I² = 12%). Non-randomised cohorts were concordant (0.76, 0.59–0.96). Benefit was greatest in combined IFG+IGT (0.66, 0.52–0.83), intermediate in isolated IGT (0.80, 0.64–0.99) and absent in isolated IFG (0.90, 0.55–1.47); in the DPP/DPPOS, benefit was concentrated in women with prior gestational diabetes (HR 0.59 vs 0.94; P for interaction = 0.02), fasting glucose 110–125 mg/dL and age below 60 years, and persisted over 21 years (HR 0.83, 0.74–0.93). Metformin increased reversion to normoglycaemia (RR 1.26, 1.08–1.46), and modestly reduced body weight (mean difference [MD] −1.48 kg), fasting plasma glucose (MD −0.13 mmol/L) and HbA1c (MD −0.07%). Discontinuation due to adverse events (RR 5.64, 1.82–17.51) and biochemical vitamin B12 deficiency (RR 1.85 at 5 years) were increased, whereas serious adverse events were not (RR 0.89, 0.47–1.69). The number needed to treat ranged from 13 at a 30% baseline risk to eight at a 47% baseline risk. Egger’s test suggested small-study effects (P = 0.019). Discussion: Metformin produces a reproducible, durable but moderate reduction in progression to T2DM that is smaller than that of intensive lifestyle intervention, partly attenuated after discontinuation, and strongly modified by glycaemic phenotype, adiposity, age and gestational diabetes history. Pragmatic stepwise strategies that reserve metformin for persistently high-risk individuals achieve comparable relative benefit with lower drug exposure, which is particularly relevant to Asian populations with high conversion rates. Long-term microvascular and cardiovascular benefits have not been demonstrated. Conclusion: Metformin is an effective, safe and inexpensive adjunct for preventing T2DM in adults with prediabetes, with the greatest absolute benefit in those with combined IFG+IGT, fasting glucose ≥110 mg/dL, HbA1c 6.0–6.4%, body mass index ≥35 kg/m², age below 60 years or prior gestational diabetes. It should be targeted rather than universal, integrated into stepwise lifestyle-first programmes, and accompanied by periodic vitamin B12 monitoring.
No takes yet. Share an insight, caveat, or question.
M. Khairu Rizki (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: